벤조디아제핀계 약제 시장 : 제품별, 약물 종류별, 적응증별, 투여 경로별, 유통 채널별, 세계 예측(2024-2032년)

The Benzodiazepine Drugs Market is expected to garner a CAGR of 3.9% during 2024-2032, driven by rising cases of anxiety disorders, increasing awareness regarding mental health issues, and expanding geriatric population.

According to WHO, approximately 4% of the world's population is currently affected by anxiety disorders. Across the globe, there has been an increase in the incidence of anxiety disorders, including conditions like panic disorder and social anxiety disorder. This surge in prevalence is attributed to various factors, including societal stressors, economic uncertainties, and lifestyle changes. As individuals seek effective treatment options to manage their symptoms and improve their quality of life, the demand for benzodiazepine drugs, known for their anxiolytic properties, continues to escalate. Additionally, the availability of benzodiazepines as a first-line pharmacological intervention for anxiety disorders further contributes to their widespread usage, driving market growth in the pharmaceutical sector.

The Benzodiazepine Drugs industry is classified based on product, drug class, indication, route of administration, distribution channel, and region.

The Diazepam segment will record a healthy growth rate through 2032, owing to the anxiolytic, sedative, and muscle relaxant properties of diazepam and its usage in the management of anxiety disorders, muscle spasms, and alcohol withdrawal symptoms. Its versatility in treating various conditions, in line with its effectiveness and relatively low cost, has contributed to its significant market share. Moreover, the availability of generic formulations has further propelled the adoption of diazepam.

The insomnia segment will amass a decent benzodiazepine drugs market share by 2032, attributed to high stress levels, lifestyle changes, and the growing aging population. Benzodiazepines, including diazepam and other derivatives such as temazepam and lorazepam, are commonly prescribed for short-term management of insomnia due to their sedative-hypnotic properties. However, concerns regarding their potential for dependency and adverse effects have led to greater scrutiny and the exploration of alternative treatment modalities.

Asia Pacific Benzodiazepine Drugs Industry will grow rapidly from 2024 to 2032, driven by a large population base, increasing prevalence of mental health disorders, and improving healthcare infrastructure. Moreover, the rising disposable income levels and growing awareness regarding mental health ailments are further contributing to the uptake of benzodiazepine drugs. Countries such as China, India, and Japan could be at the forefront of market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of anxiety disorders
    • 3.2.1.2 Rising geriatric population
    • 3.2.1.3 Increased incidence of insomnia
    • 3.2.1.4 Advancements in drug formulations
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Associated side effects
    • 3.2.2.2 Abuse potential and regulatory restrictions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Alprazolam
• 5.3 Diazepam
• 5.4 Lorazepam
• 5.5 Clonazepam
• 5.6 Temazepam
• 5.7 Oxazepam
• 5.8 Chlordiazepoxide
• 5.9 Other products

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Ultra-short acting
• 6.3 Short acting
• 6.4 Long acting

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Anxiety
• 7.3 Insomnia
• 7.4 Alcohol withdrawal
• 7.5 Seizures
• 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Parenteral
• 8.4 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail drug stores
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amneal Pharmaceuticals LLC.
• 11.3 Bausch Health Companies Inc.
• 11.4 Boehringer Ingelheim International GmbH
• 11.5 F. Hoffmann-La Roche Ltd.
• 11.6 GlaxoSmithKline Plc.
• 11.7 Hikma Pharmaceuticals PLC
• 11.8 Mylan N.V.
• 11.9 Novartis AG
• 11.10 Pfizer Inc.
• 11.11 Sanofi
• 11.12 Teva Pharmaceutical Industries Ltd.